<?xml version="1.0" encoding="utf-8"?> <feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom"> <title type="text">Elevai Labs Inc.</title> <subtitle type="text">Contains the last 20 releases</subtitle> <id>uuid:2e7c86fd-152f-4143-a5bb-2399e376deaf;id=41852</id> <rights type="text">Copyright 2024, Elevai Labs Inc.</rights> <updated>2024-11-04T22:45:39Z</updated> <author> <name>newsdesk@globenewswire.com (NewsDesk)</name> <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri> <email>newsdesk@globenewswire.com</email> </author> <link rel="alternate" href="https://www.globenewswire.com/atomfeed/organization/m1XTUjN4ingSwRd04cXIZw==" /> <link rel="self" href="https://www.globenewswire.com/atomfeed/organization/m1XTUjN4ingSwRd04cXIZw==" /> <entry> <id>https://www.globenewswire.com/news-release/2024/11/04/2974528/0/en/Elevai-Labs-Inc-Announces-Update-and-Extension-of-Pending-Offer-to-Exchange.html</id> <title type="text">Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange</title> <published>2024-11-04T22:45:39Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/11/04/2974528/0/en/Elevai-Labs-Inc-Announces-Update-and-Extension-of-Pending-Offer-to-Exchange.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange]]></content> <dc:identifier>2974528</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Mon, 04 Nov 2024 22:45 GMT</dc:modified> <dc:subject>Major shareholder announcements</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/10/22/2967072/0/en/Elevai-Biosciences-a-Subsidiary-of-Elevai-Labs-Inc-Engages-Leading-Contract-Research-Organization-CRO-to-Support-Regulatory-Planning-Efforts-and-Pre-IND-Meeting-with-the-Food-and-D.html</id> <title type="text">Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity</title> <published>2024-10-22T13:54:26Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/10/22/2967072/0/en/Elevai-Biosciences-a-Subsidiary-of-Elevai-Labs-Inc-Engages-Leading-Contract-Research-Organization-CRO-to-Support-Regulatory-Planning-Efforts-and-Pre-IND-Meeting-with-the-Food-and-D.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Biosciences Engages Leading CRO to Support Regulatory Planning Efforts and Pre-IND Meeting with the FDA for EL-22 For The Treatment of Obesity]]></content> <dc:identifier>2967072</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Tue, 22 Oct 2024 13:54 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:keyword>Activan A</dc:keyword> <dc:keyword>bioscience</dc:keyword> <dc:keyword>ELAB</dc:keyword> <dc:keyword>GLP1</dc:keyword> <dc:keyword>Mounjaro</dc:keyword> <dc:keyword>muscle loss prevention</dc:keyword> <dc:keyword>myostatin</dc:keyword> <dc:keyword>nasdaq</dc:keyword> <dc:keyword>Obesity</dc:keyword> <dc:keyword>Ozempic</dc:keyword> <dc:keyword>semaglutide</dc:keyword> <dc:keyword>Weight Loss</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/10/21/2966100/0/en/Elevai-Biosciences-a-Subsidiary-of-Elevai-Labs-Inc-Highlights-Past-Positive-Preclinical-Data-Showing-Potential-of-EL-32-A-Dual-Myostatin-Activin-A-Blocker-For-the-Treatment-of-Obes.html</id> <title type="text">Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity</title> <published>2024-10-21T11:30:00Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/10/21/2966100/0/en/Elevai-Biosciences-a-Subsidiary-of-Elevai-Labs-Inc-Highlights-Past-Positive-Preclinical-Data-Showing-Potential-of-EL-32-A-Dual-Myostatin-Activin-A-Blocker-For-the-Treatment-of-Obes.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl]]></content> <dc:identifier>2966100</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Mon, 21 Oct 2024 11:30 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Clinical Study</dc:subject> <dc:keyword>Activan A</dc:keyword> <dc:keyword>bioscience</dc:keyword> <dc:keyword>ELAB</dc:keyword> <dc:keyword>GLP1</dc:keyword> <dc:keyword>Mounjaro</dc:keyword> <dc:keyword>muscle loss prevention</dc:keyword> <dc:keyword>NASDAQ: ELAB</dc:keyword> <dc:keyword>myostatin</dc:keyword> <dc:keyword>Obesity</dc:keyword> <dc:keyword>Ozempic</dc:keyword> <dc:keyword>semaglutide</dc:keyword> <dc:keyword>wegovy</dc:keyword> <dc:keyword>Weight Loss</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/10/04/2958524/0/en/Elevai-Labs-Inc-Commences-Offer-to-Exchange-Up-to-15-000-000-shares-of-Common-Stock-For-Shares-of-Non-Tradable-Locked-Up-Series-B-Preferred-Stock.html</id> <title type="text">Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock</title> <published>2024-10-04T21:08:26Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/10/04/2958524/0/en/Elevai-Labs-Inc-Commences-Offer-to-Exchange-Up-to-15-000-000-shares-of-Common-Stock-For-Shares-of-Non-Tradable-Locked-Up-Series-B-Preferred-Stock.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock]]></content> <dc:identifier>2958524</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Fri, 04 Oct 2024 21:09 GMT</dc:modified> <dc:subject>Changes in share capital and votes</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/10/03/2957992/0/en/REPEAT-Elevai-Biosciences-a-Subsidiary-of-Elevai-Labs-Inc-Expands-Patent-Portfolio-with-Two-New-Filings-for-EL-22-in-Muscle-Loss-Treatment-for-Obese-Patients-Including-GLP-1-Recept.html</id> <title type="text">REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations</title> <published>2024-10-03T19:45:00Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/10/03/2957992/0/en/REPEAT-Elevai-Biosciences-a-Subsidiary-of-Elevai-Labs-Inc-Expands-Patent-Portfolio-with-Two-New-Filings-for-EL-22-in-Muscle-Loss-Treatment-for-Obese-Patients-Including-GLP-1-Recept.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,]]></content> <dc:identifier>2957992</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Thu, 03 Oct 2024 19:45 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Patents</dc:subject> <dc:keyword>Activan A</dc:keyword> <dc:keyword>bioscience</dc:keyword> <dc:keyword>ELAB</dc:keyword> <dc:keyword>finance</dc:keyword> <dc:keyword>GLP1</dc:keyword> <dc:keyword>Mounjaro</dc:keyword> <dc:keyword>muscle loss prevention</dc:keyword> <dc:keyword>myostatin</dc:keyword> <dc:keyword>NASDAQ: ELAB</dc:keyword> <dc:keyword>Obesity</dc:keyword> <dc:keyword>Ozempic</dc:keyword> <dc:keyword>semaglutide</dc:keyword> <dc:keyword>wegovy</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/10/03/2957611/0/en/Elevai-Biosciences-a-Subsidiary-of-Elevai-Labs-Inc-Expands-Patent-Portfolio-with-Two-New-Filings-for-EL-22-in-Muscle-Loss-Treatment-for-Obese-Patients-Including-GLP-1-Receptor-Agon.html</id> <title type="text">Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations</title> <published>2024-10-03T11:30:00Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/10/03/2957611/0/en/Elevai-Biosciences-a-Subsidiary-of-Elevai-Labs-Inc-Expands-Patent-Portfolio-with-Two-New-Filings-for-EL-22-in-Muscle-Loss-Treatment-for-Obese-Patients-Including-GLP-1-Receptor-Agon.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,]]></content> <dc:identifier>2957611</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Thu, 03 Oct 2024 11:30 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Patents</dc:subject> <dc:keyword>Activan A</dc:keyword> <dc:keyword>ELAB</dc:keyword> <dc:keyword>bioscience</dc:keyword> <dc:keyword>GLP1</dc:keyword> <dc:keyword>myostatin</dc:keyword> <dc:keyword>Weight Loss</dc:keyword> <dc:keyword>muscle loss prevention</dc:keyword> <dc:keyword>Obesity</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/10/02/2956947/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Inc-Announces-Launch-of-Clinical-Study-Combining-Its-Flagship-Topical-Exosome-Skincare-Products-with-a-Medical-Aesthetic-Energy-Device.html</id> <title type="text">Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device</title> <published>2024-10-02T12:30:00Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/10/02/2956947/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Inc-Announces-Launch-of-Clinical-Study-Combining-Its-Flagship-Topical-Exosome-Skincare-Products-with-a-Medical-Aesthetic-Energy-Device.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medic]]></content> <dc:identifier>2956947</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Wed, 02 Oct 2024 12:31 GMT</dc:modified> <dc:subject>Clinical Study</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>exosomes</dc:keyword> <dc:keyword>regenerative</dc:keyword> <dc:keyword>skincare</dc:keyword> <dc:keyword>Skincare Innovation</dc:keyword> <dc:keyword>Skincare Technology</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/09/23/2951407/0/en/Elevai-Labs-Inc-Announces-Pricing-of-8-0-Million-Public-Offering.html</id> <title type="text">Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering</title> <published>2024-09-23T12:45:00Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/09/23/2951407/0/en/Elevai-Labs-Inc-Announces-Pricing-of-8-0-Million-Public-Offering.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">NEWPORT BEACH, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold.<br></p>]]></content> <dc:identifier>2951407</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Mon, 23 Sep 2024 12:45 GMT</dc:modified> <dc:subject>Financing Agreements</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/09/10/2943558/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Inc-Announces-Positive-Results-for-E-Series-Exosome-Technology-in-Potential-Melasma-Applications.html</id> <title type="text">Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications</title> <published>2024-09-10T11:30:24Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/09/10/2943558/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Inc-Announces-Positive-Results-for-E-Series-Exosome-Technology-in-Potential-Melasma-Applications.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications]]></content> <dc:identifier>2943558</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Tue, 10 Sep 2024 11:31 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Clinical Study</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>skincare</dc:keyword> <dc:keyword>exosomes</dc:keyword> <dc:keyword>NASDAQ: ELAB</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/09/03/2939574/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Inc-Announces-Encouraging-Data-Results-Indicating-Potential-for-Hair-Restoration-Using-Proprietary-Exosome-Technology.html</id> <title type="text">Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology</title> <published>2024-09-03T11:30:00Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/09/03/2939574/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Inc-Announces-Encouraging-Data-Results-Indicating-Potential-for-Hair-Restoration-Using-Proprietary-Exosome-Technology.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Labs Inc. Subsidiary, Elevai Skincare Inc. Announces Encouraging Research Data Results Indicating Potential for Hair Restoration Using Proprietary]]></content> <dc:identifier>2939574</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Tue, 03 Sep 2024 11:30 GMT</dc:modified> <dc:subject>Partnerships</dc:subject> <dc:subject>Clinical Study</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>exosomes</dc:keyword> <dc:keyword>skincare</dc:keyword> <dc:keyword>hair and scalp care</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/08/28/2936908/0/en/Elevai-Labs-Inc-Files-Combination-Patents-with-Yuva-Biosciences-for-Breakthrough-Hair-and-Scalp-Care-Technology-Utilizing-YuvaBio-Y100-Mitochondrial-Innovation-and-Elevai-Exosomes.html</id> <title type="text">Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™</title> <published>2024-08-28T11:30:00Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/08/28/2936908/0/en/Elevai-Labs-Inc-Files-Combination-Patents-with-Yuva-Biosciences-for-Breakthrough-Hair-and-Scalp-Care-Technology-Utilizing-YuvaBio-Y100-Mitochondrial-Innovation-and-Elevai-Exosomes.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondria]]></content> <dc:identifier>2936908</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Wed, 28 Aug 2024 11:30 GMT</dc:modified> <dc:subject>Patents</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>hair and scalp care</dc:keyword> <dc:keyword>NASDAQ: ELAB</dc:keyword> <dc:keyword>exosomes</dc:keyword> <dc:keyword>hair loss</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/08/26/2935402/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Inc-Announces-Positive-Data-Results-with-Completion-of-Clinical-Study-of-Elevai-Enfinity-Topical-Exosome-Serum.html</id> <title type="text">Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum</title> <published>2024-08-26T11:30:00Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/08/26/2935402/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Inc-Announces-Positive-Data-Results-with-Completion-of-Clinical-Study-of-Elevai-Enfinity-Topical-Exosome-Serum.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai EnfinityTM]]></content> <dc:identifier>2935402</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Mon, 26 Aug 2024 11:30 GMT</dc:modified> <dc:subject>Clinical Study</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>exosomes</dc:keyword> <dc:keyword>skincare</dc:keyword> <dc:keyword>regenerative</dc:keyword> <dc:keyword>Skincare Innovation</dc:keyword> <dc:keyword>Skincare Technology</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/08/19/2932144/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Research-Inc-Announces-Preliminary-Positive-Research-Data-Highlighting-the-Potential-of-Proprietary-Exosome-Technology-for-Skin-Health-Application.html</id> <title type="text">Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications</title> <published>2024-08-19T13:00:00Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/08/19/2932144/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Research-Inc-Announces-Preliminary-Positive-Research-Data-Highlighting-the-Potential-of-Proprietary-Exosome-Technology-for-Skin-Health-Application.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data]]></content> <dc:identifier>2932144</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Mon, 19 Aug 2024 13:00 GMT</dc:modified> <dc:subject>Clinical Study</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>exosomes</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/08/14/2930133/0/en/Elevai-Labs-Inc-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Business-Update.html</id> <title type="text">Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update</title> <published>2024-08-14T13:05:44Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/08/14/2930133/0/en/Elevai-Labs-Inc-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Business-Update.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update]]></content> <dc:identifier>2930133</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Wed, 14 Aug 2024 13:06 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>exosomes</dc:keyword> <dc:keyword>GLP1</dc:keyword> <dc:keyword>Obesity</dc:keyword> <dc:keyword>NASDAQ: ELAB</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/07/30/2921052/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Biosciences-Continues-to-Advance-its-Scientific-Advisory-Board-with-the-Appointment-of-Orian-Shirihai-MD-PhD.html</id> <title type="text">Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD</title> <published>2024-07-30T13:00:26Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/07/30/2921052/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Biosciences-Continues-to-Advance-its-Scientific-Advisory-Board-with-the-Appointment-of-Orian-Shirihai-MD-PhD.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD]]></content> <dc:identifier>2921052</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Tue, 30 Jul 2024 13:01 GMT</dc:modified> <dc:subject>Directors and Officers</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>exosomes</dc:keyword> <dc:keyword>GLP1</dc:keyword> <dc:keyword>muscle loss prevention</dc:keyword> <dc:keyword>myostatin</dc:keyword> <dc:keyword>NASDAQ: ELAB</dc:keyword> <dc:keyword>Obesity</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/06/28/2905886/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Announces-The-Elevai-S-Series-Hair-and-Scalp-Care-Product-Line.html</id> <title type="text">Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line</title> <published>2024-06-28T13:00:00Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/06/28/2905886/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-Announces-The-Elevai-S-Series-Hair-and-Scalp-Care-Product-Line.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line]]></content> <dc:identifier>2905886</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Fri, 28 Jun 2024 13:00 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>NASDAQ: ELAB</dc:keyword> <dc:keyword>regenerative</dc:keyword> <dc:keyword>Skincare Innovation</dc:keyword> <dc:keyword>Skincare Technology</dc:keyword> <dc:keyword>hair loss</dc:keyword> <dc:keyword>hair and scalp care</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/06/26/2904555/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-to-Debut-Upcoming-New-Product-Line-at-The-Aesthetic-Show-2024.html</id> <title type="text">Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024</title> <published>2024-06-26T13:00:00Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/06/26/2904555/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Skincare-to-Debut-Upcoming-New-Product-Line-at-The-Aesthetic-Show-2024.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024]]></content> <dc:identifier>2904555</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Wed, 26 Jun 2024 13:01 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>NASDAQ: ELAB</dc:keyword> <dc:keyword>skincare</dc:keyword> <dc:keyword>Skincare Innovation</dc:keyword> <dc:keyword>Skincare Technology</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/06/14/2899006/0/en/Elevai-Labs-Forms-New-Scientific-Advisory-Board-for-its-Weight-Loss-Programs.html</id> <title type="text">Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs</title> <published>2024-06-14T13:00:00Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/06/14/2899006/0/en/Elevai-Labs-Forms-New-Scientific-Advisory-Board-for-its-Weight-Loss-Programs.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs]]></content> <dc:identifier>2899006</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Fri, 14 Jun 2024 13:00 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> <dc:keyword>ELAB</dc:keyword> <dc:keyword>myostatin</dc:keyword> <dc:keyword>Obesity</dc:keyword> <dc:keyword>GLP1</dc:keyword> <dc:keyword>Weight Loss</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/05/29/2889949/0/en/Elevai-Labs-Subsidiary-Elevai-Skincare-to-Present-at-the-Beauty-Through-Science-Conference-in-Stockholm.html</id> <title type="text">Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm</title> <published>2024-05-29T13:00:00Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/05/29/2889949/0/en/Elevai-Labs-Subsidiary-Elevai-Skincare-to-Present-at-the-Beauty-Through-Science-Conference-in-Stockholm.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm]]></content> <dc:identifier>2889949</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Wed, 29 May 2024 13:01 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> <dc:keyword>bioscience</dc:keyword> <dc:keyword>ELAB</dc:keyword> <dc:keyword>NASDAQ: ELAB</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/05/22/2886862/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Biosciences-to-Present-at-the-UCLA-LA-BEST-2024-Conference.html</id> <title type="text">Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference</title> <published>2024-05-22T20:15:00Z</published> <updated>2024-11-13T20:18:19Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/05/22/2886862/0/en/Elevai-Labs-Inc-Subsidiary-Elevai-Biosciences-to-Present-at-the-UCLA-LA-BEST-2024-Conference.html" /> <category term="Nasdaq:ELAB" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US28622K1043" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference]]></content> <dc:identifier>2886862</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Elevai Labs Inc.</dc:contributor> <dc:modified>Wed, 22 May 2024 20:15 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> <dc:keyword>NASDAQ: ELAB</dc:keyword> <dc:keyword>GLP1</dc:keyword> <dc:keyword>ELAB</dc:keyword> <dc:keyword>finance</dc:keyword> <dc:keyword>muscle loss prevention</dc:keyword> <dc:keyword>myostatin</dc:keyword> </entry> </feed>